Bone Biologics Corp
As of Oct 22, 2026, Bone Biologics is in Stage 4, the downtrend phase, now in week 14 (since Jul 22, 2026). It closed at $0.41, 81.9% below its 52-week high and below its 200-day average, which is falling.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BBLG early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BBLG among Biotechnology482nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …482 | BBLG | Stage 4 · wk 14 | 10 | −19.8% |
Bone Biologics: quick answers
What stage is Bone Biologics in?
As of Oct 22, 2026, Bone Biologics (BBLG) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 22, 2026 and is in week 14. What the four stages mean
Is Bone Biologics in an uptrend?
No. Bone Biologics is in a Stage 4 downtrend. It trades 63.0% below its 200-day average, which is falling.
How far is Bone Biologics from its 52-week high?
Bone Biologics closed at $0.41 on Oct 22, 2026, 81.9% below its 52-week high of $2.24. Its 52-week low is $0.39.
How has Bone Biologics performed over the past year?
As of Oct 22, 2026, Bone Biologics is down 83.4% over the past year and down 73.6% so far in 2026.
Which sector and industry is Bone Biologics in?
Bone Biologics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.